The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 5, 2003, Pages 907-914

  Al Dieri, R ^a   Wagenvoord, R ^a   Van Dedem, G W K ^b   Begun S ^a   Hemker, H C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Antifactor Xa activity; Antithrombin activity; Heparin; Pentasaccharide; Thrombin generation

Indexed keywords

EID: 0345079919     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00211.x     Document Type: Article

References (32)

1. Hirsh J. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Aust NZ J Med 1992; 22: 487-95.
2. Cosmi B, Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 1994; 9: 612-8.
3. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996; 22 (Suppl. 1): 77-91.
4. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: are they different? Can J Cardiol 1998; 14 (Suppl. E): 28E-34E.
5. Barrowcliffe TW. LMW heparin: relationship between antithrombotic and anticoagulant effects. Adv Exp Med Biol 1992; 313: 205-20.
6. Begum S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62.
7. Bendetowicz AV, Pacaud E, Béguin S, Uzan A, Hemker HC. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin). Thromb Haemost 1992; 67: 556-62.
8. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma-a study in human volunteers. Thromb Haemost 1994; 72: 705-12.
9. Bendetowicz AV, Béguin S, Caplain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin- a three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13.
10. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
11. Lane DA, MacGregor IR, VanRoss M, Cella G, Kakkar VV. Molecular weight dependence of the anticoagulant properties of heparin: intrave nous and subcutaneous administration of fractionated heparins to man. Thromb Res 1979; 16: 651-62.
12. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32.
13. Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussay P, Lormeau JC, Herbert JM. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-22.
14. Hemker HC, Béguin S. Standard and method independent units for heparin anticoagulant activities. Thromb Haemost 1993; 70: 724-8.
15. Béguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refuta tions on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29: 170-8.
16. Béguin S, Dol F, Hemker HC. Factor IXa inhibition contributes to the heparin effect. Thromb Haemost 1991; 66: 306-9.
17. Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker MC, Béguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
18. Bock PE, Craig PA, Olson ST, Singh P. Isolation of human blood coagulation alpha-factor Xa by soybean trypsin inhibitor-Sepharose chromatography and its active-site titration with fluorescein mono-p-guanidinobenzoate. Arch Biochem Biophys 1989; 273: 375-88.
19. Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purifica tion of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
20. Bajaj SP, Mann KG. Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem 1973; 248: 7729-41.
21. Rijkers DT, Wielders S, Tesser GI, Hemker HC. Design and synthesis of thrombin substrates with modified kinetic parameters. Thromb Res 1995; 79: 491-9.
22. Einarsson R, Andersson LO. Binding of heparin to human antithrombin III as studied by measurements of tryptophan fluorescence. Biochim Biophys Acta 1977; 490: 104-11.
23. Schoen P, Wielders S, Petitou M, Lindhout T. The effect of sulfation on the anticoagulant and antithrombin III-binding properties of a heparin fraction with low affinity for antithrombin III. Thromb Res 1990; 57: 415-23.
24. Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antith rombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemost 1992; 68: 136-42.
25. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
26. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
27. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini PL. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297-306.
28. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49: 10-4.
29. Hemker HC, Béguin S, Bendetowicz AV, Wielders S. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection. Haemostasis 1991; 21: 258-72.
30. Robinson HC, Horner AA, Hook M, Ogren S, Lindahl U. A proteogly-can form of heparin and its degradation to single-chain molecules. JBiol Chem 1978; 253: 6687-93.
31. Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, anddermatan sulfate. Circulation 1997; 95: 118-24.
32. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasac charide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.